NCT03219632已完成不适用
Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 72
- 主要终点
- The change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG (composite).
研究概览
简要总结
Assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients
详细描述
Patients who were diagnosed with left ventricular hypertrophy (LVH) by ECG at the start of the study are followed up at 3-month intervals for 1 year.
Increase Fimasartan if blood pressure is not controlled.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have been treated or not treated with hypertension from 20 to 80 years of age
- •Patients with electrocardiographic left ventricular hypertrophy (In this study, we define left ventricular hypertrophy if one of the following two criteria is met)
- •RaVL+SV3 > 20mm(M). 16mm(F)
- •SV1+RV5 or RV6 > 35mm.
- •Patients who are taking or expecting Fimasartan
排除标准
- •Patients with unstable angina or myocardial infarction within 3 months
- •Patients with clinically significant severe valve disease, congenital heart disease, peripheral vascular disease, cerebrovascular disease
- •Clinically significant severe congestive heart failure patients
- •Patients with renal dialysis
- •Clinically significant renal disease patients
- •Patients with clinically significant hepatic impairment
- •Patients with a history of alcohol or substance abuse
- •Patients with hypersensitivity to angiotensin-receptor blocker
- •Patients needing angiotensin-receptor blocker drugs other than fimasartan
- •For women, pregnancy, Patients who are breastfeeding or planning to become pregnant
- •A person who is determined to be inappropriate by the Investigator
- •Patients participating in other clinical trials
结局指标
主要结局
The change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG (composite).
时间窗: 1 year
Measurements of changes in baseline at 12 months (change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG)
次要结局
未报告次要终点
研究者
Dong-Ju Choi
Professor, MD, PhD
Seoul National University Bundang Hospital
相似试验
Unknown
4 期
Comparison of Blood Pressure Lowering Effect Between Fimasartan and LosartanHypertensionNCT02958631Chuncheon Sacred Heart Hospital40
已完成
3 期
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension PatientsHypertensionNCT00922480Boryung Pharmaceutical Co., Ltd506
已完成
不适用
Study of the Fimasartan effects on cardiovascular events and metabolic syndrome in patients with hypertensioDiseases of the circulatory systemKCT0000529Cheil General Hospital & Women's healthcare center20,000
终止
3 期
Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)HypertensionNCT00738972Fundación Lindavista del Corazón AC12
已完成
4 期
Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular HypertrophyLeft Ventricular HypertrophyHypertensionNCT01425411Mustafa Kemal University38